Related Experiment Video
Updated: Oct 29, 2026

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
Published on: July 18, 2025
Metabolic Dysfunction-Associated Steatotic Liver Disease in Children
Toshifumi Yodoshi1, Stavra Xanthakos2
1Division of Gastroenterology, Hepatology, Pancreatology, and Nutrition, Department of Pediatrics, Stead Family Children's Hospital, University of Iowa, 200 Hawkins Drive, Iowa City, IA 52242, USA; Division of Gastroenterology, Hepatology and Nutrition, Cincinnati Children's Hospital, 3333 Burnet Avenue, Cincinnati, OH 45229, USA.
Abstract:
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent chronic liver disease among children and adolescents worldwide. Pediatric MASLD is associated with significant morbidity during childhood, including progressive liver fibrosis and incident diabetes, and significantly increases risk of premature mortality in early adulthood. In comparison to MASLD in adults, youth-onset MASLD exhibits distinct histologic patterns, lacks well-validated noninvasive tests for risk stratification and approved pharmacotherapy, and may carry higher risk of long-term liver-related mortality. Critical areas of unmet need include improving rates of recommended screening, development of pediatric-specific risk stratification tools and developing more effective prevention and treatment strategies.
Related Concept Videos
Inborn Errors of Metabolism
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Liver Regeneration
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are large...